// App-Quantinova.ai

POS0193 (2022) : EVALUATION OF CRESS IN THE PHASE 2 RANDOMISED PLACEBO-CONTROLLED STUDY OF SEQUENTIAL BELIMUMAB/RITUXIMAB ADMINISTRATION IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME

Researchers

Presenter

  • H. Bootsma

Principal Investigators

  • S. Arends

  • L. de Wolff

  • K. L. Clark

  • A. van Maurik

  • P. Mistry

  • P. Shukla

  • S. Nihtyanova

  • N. L. Fox

  • D. Roth

Medical Centers

  • University Medical Center Groningen, University of Groningen, Department of Rheumatology and Clinical Immunology, Groningen, Netherlands

  • GlaxoSmithKline, Clinical Science, London, United Kingdom

  • GlaxoSmithKline, Clinical Pharmacology and Experimental Medicine, Stevenage, Hertfordshire, United Kingdom

  • GlaxoSmithKline, R&D Biostatistics, Stevenage, United Kingdom

  • GlaxoSmithKline, R&D Biostatistics, Bangalore, India

  • GlaxoSmithKline, Clinical Science, London, United Kingdom

  • GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, United States of America

  • GlaxoSmithKline plc, Collegeville, United States of America

Locations

  • Netherlands

  • United Kingdom

  • India

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Sjogren's syndrome

Biomarkers

  • Immunoglobulin G

Drug/Treatment

  • Belimumab

  • Rituximab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • II

Study Id's

  • NCT02631538

Sponsors

  • Bernhard Schulte Shipmanagement (BSM) and Roche

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved